Media Resources
Explore our recent press releases to stay updated on Keenova’s news, advancements, and contributions in the healthcare sector.
Press Releases
Mallinckrodt Reports Third Quarter 2025 Financial Results
Mallinckrodt Completes Spin-Off of Par Health, Introduces Keenova Therapeutics
Mallinckrodt to Present Data on Terlipressin at the 2025 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Mallinckrodt to Present Data on Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at Kidney Week 2025
Mallinckrodt plc to Report Third Quarter 2025 Financial Results on November 10, 2025
Mallinckrodt Recognizes First Hepatorenal Syndrome (HRS) Awareness Day
Mallinckrodt Names Dr. Marek J. Honczarenko as EVP and Chief Scientific Officer
Mallinckrodt Announces Publication of Findings on Treatment Patterns and Outcomes in Patients with Two Types of Arthritis Treated with Acthar® Gel (repository corticotropin injection)
Mallinckrodt Names Christiana Stamoulis as President and Chief Financial Officer
Mallinckrodt plc Reports Financial Results for Second Quarter 2025 and Provides Guidance
Media Contact
For information not available on this site, members of the press may email requests to our corporate communications team using the form below.